Victory Capital Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Victory Capital Management’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-69,102	Closed	-$27.5K	–	2729
2022 Q4	$27.5K	Sell	69,102 -5,336	-7%	-$3.51K	﹤0.01%	2498
2022 Q3	$58K	Sell	74,438 -24	-0%	-$50	﹤0.01%	2551
2022 Q2	$214K	Sell	74,462 -121,972	-62%	-$428K	﹤0.01%	2333
2022 Q1	$985K	Sell	196,434 -14,226	-7%	-$89.3K	﹤0.01%	1822
2021 Q4	$2.35M	Sell	210,660 -18,091	-8%	-$251K	﹤0.01%	1506
2021 Q3	$3.73M	Sell	228,751 -1,429	-0.6%	-$25.6K	﹤0.01%	1407
2021 Q2	$4.27M	Sell	230,180 -44,280	-16%	-$850K	﹤0.01%	1395
2021 Q1	$4.14M	Buy	274,460 +180,157	+191%	+$3.92M	﹤0.01%	1410
2020 Q4	$3.05M	Buy	+94,303	New	+$1.25M	﹤0.01%	1378

Other funds holding CDAK

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management's CDAK Position: Q1 2023 in Review

Victory Capital Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 69,102 shares — an estimated $27.5K sold.

Victory Capital Management first reported a position in CDAK in Q4 2020 and held it in 9 quarters. The position peaked at $4.27M in Q2 2021. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

Victory Capital Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Victory Capital Management sold 69,102 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $27.5K.
Victory Capital Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Victory Capital Management's Codiak BioSciences, Inc. Common Stock position peaked at $4.27M in Q2 2021.
27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Victory Capital Management's 13F filing for Q1 2023, filed 2 May 2023.